Key result
This review discusses the pharmacology and clinical trial data of the reversibly-binding P2Y12 inhibitors ticagrelor, cangrelor, and elinogrel compared with clopidogrel and prasugrel.
Comparison
Reversibly-binding P2Y12 inhibitors vs Thienopyridines (clopidogrel and prasugrel)
Design
Review
Authors
Loading...
Reversible P2Y12 inhibitors expand options beyond clopidogrel; leaves open optimal selection pending completed phase 3 data.
This review summarizes the pharmacology and clinical trial data of novel reversibly-binding P2Y12 inhibitors compared to traditional thienopyridines.
Robert F. Storey (2011) reported a review. Reversibly-binding P2Y12 inhibitors (ticagrelor, cangrelor, elinogrel) vs. Thienopyridines (clopidogrel, prasugrel) was evaluated. This review discusses the pharmacology and clinical trial data of the reversibly-binding P2Y12 inhibitors ticagrelor, cangrelor, and elinogrel compared with clopidogrel and prasugrel.